Duration of treatment for osteoporosis

DOI https://doi.org/10.4081/reumatismo.2013.22

Article Sidebar

PDF
Published: Mar 28, 2013
Articles

Issue
Vol 65, No 1 (2013)
Pages
22-35
Keywords
Osteoporosis, duration, treatment, alendronate, denosumab.
Statistics
Abstract Views: 2761

PDF: 857
Share it
How to Cite
Idolazzi, L., Fassio, A., Gatti, D., Tamanini, S., Viapiana, O., Rossini, M., & Adami, S. (2013). Duration of treatment for osteoporosis. Reumatismo, 65(1), 22-35. https://doi.org/10.4081/reumatismo.2013.22
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Main Article Content

Luca Idolazzi
Unità di Reumatologia, Dipartimento di Medicina, Università di Verona, Italy.
A. Fassio
Rheumatology Unit, University of Verona, Italy.
D. Gatti
Rheumatology Unit, University of Verona, Italy.
S. Tamanini
Rheumatology Unit, University of Verona, Italy.
O. Viapiana
Affiliation not present.
M. Rossini
Affiliation not present.
S. Adami *
Affiliation not present.
(*) Corresponding Author:
S. Adami | silvano.adami@univr.it

Abstract

Many treatments for postmenopausal osteoporosis with proven efficacy in lowering fracture risk had become available since many years now. In the last few years the issue about treatment duration has become a matter of importance. In this paper the pivotal trials for alendronate, risedronate, zoledronate and other anti reabsorptive drugs such as denosumab are revised with particular attention to the extension studies aimed to verify the effect of drug discontinuation. The results of the review highlight differences among the available drugs and the practical clinical consequences also in terms of cost-effectiveness.

Downloads month by month

Downloads

Download data is not yet available.

Article Details

Most read articles by the same author(s)

1 2 > >>